# Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM

> **NCT06630624** · PHASE1,PHASE2 · RECRUITING · sponsor: **M.R. Meijerink** · enrollment: 120 (estimated)

## Conditions studied

- Colorectal Cancer
- Liver Metastases
- Liver Metastasis Colon Cancer

## Interventions

- **DRUG:** IP-001

## Key facts

- **NCT ID:** NCT06630624
- **Lead sponsor:** M.R. Meijerink
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-10
- **Primary completion:** 2029-08-01
- **Final completion:** 2031-08-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-07-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06630624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06630624, "Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06630624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*